Aspen acquires anticoagulant brands


South African generics manufacturer Aspen has bought two heparin-derived thrombosis drugs from GlaxoSmithKline (GSK). The £700 million deal includes Arixtra (fondaparinux) and Fraxiparine (nadroparin), as well as a manufacturing site in Notre-Dame de Bondeville, France.

Earlier this year, Aspen agreed a similarly large deal with MSD, the European subsidiary of Merck & Co, for a bundle of other drug brands and a manufacturing site in the Netherlands, which also produces heparin-based ingredients. ‘This deal presents excellent synergistic opportunities for Aspen’s ongoing global expansion strategy,’ said Aspen’s chief executive Stephen Saad in a statement. Together, the two deals will allow the firm to ‘pursue a more vertically integrated supply chain for heparin based products’.

GSK will retain distribution rights for the two drugs in China, Pakistan and India.

 


Related Content

Aspen in $1 billion deal with Merck

1 July 2013 Business

news image

South African generics manufacturer to buy 11 drug brands and an API business from the US drugmaker

Business roundup

27 January 2012 Business

news image

Industry news, February 2012

Most Read

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines

MDMA

9 October 2014 Podcast | Compounds

news image

The drug that fuelled rave culture may yet be a treatment for PTSD. Hayley Simon introduces MDMA

Most Commented

Helium happily shares electrons to create dianions

16 October 2014 Research

news image

Fullerene dianions created in nanodroplets of helium opening up new ways of creating exotic molecular species

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines